SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Sophia Genetics Q1 2025 earnings call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Tuesday, May 6, 2025. I would now like to turn the conference over to Kellen Sanger, Sophia Genetics, Head of the Strategy and Investment Relations. Please go ahead. Thank you, and good morning, everyone. Welcome to the Sophia Genetics First Quarter 2025 Earnings Conference Call. Joining me today to discuss the results are Dr. Yuri Yurikov, our Co-Founder and Chief Executive Officer, Ross Mukin, our Company President, and George Cardosa, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place under-reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release issued by Sophie Genetics today and in the documents and reports filed by Sophie Genetics from time to time to the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. a reconciliation of IFRS and non-IFRS measures to include in today's press release, which is available on our website. With that, I'll now turn the call over to Yergi. Thanks, Kellen, and good morning, everyone. I will start to...